SARS-CoV-2 Omicron XBB.1 variant outbreak in a defined cohort: an epidemiological investigation incorporating longitudinal assessment of humoral response
Recently infected individuals are protected from reinfection with newer subvariants. However, protection is likely short lived.
Authors
- Yael Weiss-Ottolenghi
- Yaniv Lustig (ORCID: https://orcid.org/0000-0001-7949-5912)
- Neta S. Zuckerman (ORCID: https://orcid.org/0000-0001-6074-2100)
- Gili Joseph (ORCID: https://orcid.org/0000-0002-2568-9751)
- Ili Margalit (ORCID: https://orcid.org/0000-0002-2622-418X)
- Victoria Indenbaum (ORCID: https://orcid.org/0000-0002-7675-0591)
- Gili Regev‐Yochay (ORCID: https://orcid.org/0000-0001-7163-4607)
- Noam Barda (ORCID: https://orcid.org/0000-0002-3400-235X)
- Einat Panet
- Yovel Peretz
Institutions
- Sheba Medical Center (IL)
- Israel Ministry of Health (IL)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1016/j.ijid.2024.107240
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Steadman Philippon Research Institute